Shimamura So, Morikawa Honami, Shinohara Ken, Ohkoshi Hiroki, Omori Chisa, Hoshino Yuuki, Uchida Yoshinori, Masafumi Saiki, Ikemura Shinnosuke, Ohishi Naoki, Kondo Tetsuo, Soejima Kenzo
Department of Respiratory Medicine, Graduate School of Medicine University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3892, Japan.
Department of Pathology, Graduate School of Medicine University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3892, Japan.
Respir Med Case Rep. 2024 May 25;50:102042. doi: 10.1016/j.rmcr.2024.102042. eCollection 2024.
There is no approved drug treatment for autoimmune pulmonary alveolar proteinosis (APAP), although traditionally requires complex treatments such as whole lung lavage (WLL). We herein report on a 67-year-old man diagnosed with APAP. Treatment with atorvastatin (5 mg daily) resulted in significant improvement in symptoms, lung function, and computed tomography findings, with enhanced oxygenation, although serum anti-GM-CSF antibody levels remained elevated. This case suggests that the remission observed in this case could potentially be attributed to a direct effect of atorvastatin within the pulmonary alveoli. Statins may be considered as one of the treatment options for APAP.
尽管传统上自身免疫性肺泡蛋白沉积症(APAP)需要如全肺灌洗(WLL)等复杂治疗,但目前尚无经批准的药物治疗方法。我们在此报告一名67岁被诊断为APAP的男性患者。阿托伐他汀(每日5毫克)治疗使症状、肺功能和计算机断层扫描结果有显著改善,氧合增强,尽管血清抗GM-CSF抗体水平仍升高。该病例表明,本病例中观察到的缓解可能潜在归因于阿托伐他汀在肺泡内的直接作用。他汀类药物可被视为APAP的治疗选择之一。